Classen Immunotherapies, Inc. v. Biogen IDEC
177 L. Ed. 2d 1119, 130 S. Ct. 3541, 561 U.S. 1040, 2010 U.S. LEXIS 5533, 79 U.S.L.W. 3006
CourtSupreme Court of the United States
DecidedJune 29, 2010
DocketNo. 08-1509
StatusPublished
Cited by2 cases
This text of 177 L. Ed. 2d 1119 (Classen Immunotherapies, Inc. v. Biogen IDEC) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Classen Immunotherapies, Inc. v. Biogen IDEC, 177 L. Ed. 2d 1119, 130 S. Ct. 3541, 561 U.S. 1040, 2010 U.S. LEXIS 5533, 79 U.S.L.W. 3006 (U.S. 2010).
Opinion
Petition for writ of cer-tiorari granted. Judgment vacated, and [1120]*1120case remanded to the United States Court of Appeals for the Federal Circuit for further consideration in light of Bilski v. Kappos, 561 U.S. 593, 130 S. Ct. 3218, 177 L. Ed. 2d 792 (2010).
Same case below, 304 Fed. Appx. 866.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Classen Immunotherapies, Inc. v. Biogen Idec
659 F.3d 1057 (Federal Circuit, 2011)
Cite This Page — Counsel Stack
Bluebook (online)
177 L. Ed. 2d 1119, 130 S. Ct. 3541, 561 U.S. 1040, 2010 U.S. LEXIS 5533, 79 U.S.L.W. 3006, Counsel Stack Legal Research, https://law.counselstack.com/opinion/classen-immunotherapies-inc-v-biogen-idec-scotus-2010.